Long-Term Follow-up of High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Children and Young Adults with Metastatic or Relapsed Ewing Sarcoma: A Single-Institution Experience
Ewing sarcoma (EWS) arises in bone and soft tissue and most commonly occurs in adolescents and young adults. With current therapy, the survival rate ranges from 75% to 80% for patients with localized disease at diagnosis [1,2]. Unfortunately, patients with metastatic disease at diagnosis have a much poorer outcome when treated with standard chemotherapy with a 3-year survival rate range between 10% and 30% [1-3]. Further, the survival rate for patients with recurrent disease also remains poor despite aggressive treatment; 5-year overall survival (OS) for patients with recurrent or progressive disease after first-line therapy ranges between 0% and 20% [3-6].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Anna B. Pawlowska, Victoria Sun, George T. Calvert, Nicole A. Karras, Judith K. Sato, Clarke P. Anderson, Jerry C. Cheng, Julie F. DiMundo, Joseph D. Femino, J'Rick Lu, Dongyun Yang, Andrew Dagis, James S. Miser, Joseph Rosenthal Source Type: research
More News: Biology | Bone Cancers | Chemotherapy | Children | Ewing's Sarcoma | Hematology | Sarcomas | Stem Cell Therapy | Stem Cells | Transplants